Direct oral anticoagulants
163 results
38 - 137
Direct oral anticoagulants associated with better outcomes than warfarin in older patients with stroke and AF (PROSPER)- Direct oral anticoagulants are noninferior to low-molecular-weight heparin to prevent recurrent VTE in adults with cancer
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism- Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
- Early initiation of direct oral anticoagulants after acute stroke with atrial fibrillation is at least as good as later initiation
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Direct oral anticoagulants (DOACs) plus clarithromycin associated with higher risk of bleed than DOACs plus azithromycin
Mitral regurgitation - Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- Aortic stenosis
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
- Concomitant use of oral anticoagulants and SSRIs associated with increased risk of major bleeding
- The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
- Antithrombotic agents in primary health care
- ACCP guidelines for antithrombotics in atrial fibrillation
- Elevated INR (> 1.5) at admission associated with increased mortality in hospitalized patients who use DOACs
- Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions
- Aspirin no different than rivaroxaban for prevention of VTE after TKA or THA
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Tranexamic acid in people on anticoagulants undergoing minor oral surgery or dental extractions
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Heart valve operation: patient follow-up and complications
- Use of antithrombotic medications increases risk of hematuria-related complications
- No benefit to continuing perioperative oral anticoagulation for patients undergoing transcatheter aortic-valve implantation
- Resuming oral anticoagulants after a bleed is associated with fewer thrombi and deaths, but more bleeds
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Prevention of venous thromboembolism
- Anticoagulant therapy for 6 weeks is noninferior to 3 months for provoked VTE in patients younger than 21 years (Kids-DOTT)
- Warfarin therapy
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Oral anticoagulation for prolonging survival in patients with cancer
- Guidelines for the perioperative management of anticoagulants and antiplatelet agents (ACCP)
- Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Deep vein thrombosis
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
- Superficial venous thrombophlebitis
- Nephrotic syndrome
- Rivaroxaban is noninferior to warfarin for valvular atrial fibrillation; also associated with fewer strokes
- Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Abelacimab has fewer bleeds than rivaroxaban, but study has several important biases
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Vitamin K for improved anticoagulation control in patients receiving warfarin
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease